Yoshiko Mizukawa

Yoshiko Mizukawa

Auto-generated profile, based on publicly available information

Yoshiko Mizukawa

Department of Dermatology Kyorin University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
YMYoshiko Mizukawa
Yoshiko Mizukawa
KHKazuhisa Hirahara
Kazuhisa Hirahara
YKYoko Kano
Yoko Kano
TSTetsuo Shiohara
Tetsuo Shiohara

1 June 2008 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YMY. Mizukawa
Y. Mizukawa
YYY. Yamazaki
Y. Yamazaki
TST. Shiohara
T. Shiohara

30 June 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MKManao Kinoshita
Manao Kinoshita
YOYouichi Ogawa
Youichi Ogawa
NHNatsumi Hama
Natsumi Hama
IUInkin Ujiie
Inkin Ujiie
AHAkito Hasegawa
Akito Hasegawa
TKTatsuyoshi Kawamura
Tatsuyoshi Kawamura
Neutrophil extracellular traps induced by drug-specific CD8 + T cells initiate SJS/TEN.

14 August 2024 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
NHNatsumi Hama
Natsumi Hama
SAShigeki Aoki
Shigeki Aoki
CCChun-Bing Chen
Chun-Bing Chen
AHAkito Hasegawa
Akito Hasegawa
YOYouichi Ogawa
Youichi Ogawa
RARiichiro Abe
Riichiro Abe
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) represent a severe spectrum of rare mucocutaneous reactions that are primarily drug-induced and characterized by significant morbidity and mortality. These conditions manifest in extensive skin detachment, distinguishing them from other generalized skin eruptions. The rarity and severity of SJS/TEN underscore the importance of accurate diagnostic criteria and effective treatments, which are currently lacking consensus. This review proposes new diagnostic criteria to improve specificity and global applicability. Recent advances in understanding the immunopathogenesis of SJS/TEN are explored, emphasizing the role of drug-specific T-cell responses and human leucocyte antigen polymorphisms in disease onset. The review also addresses current therapeutic approaches, including controversies surrounding the use of immunosuppressive agents and the emerging role of tumour necrosis factor-α inhibitors. Novel therapeutic strategies targeting specific pathogenic mechanisms, such as necroptosis and specific immune cell pathways, are discussed. Furthermore, the development of new drugs based on these insights, including targeted monoclonal antibodies and inhibitors, are examined. The review concludes by advocating for more robust and coordinated efforts across multidisciplinary medical fields to develop effective treatments and diagnostic tools for SJS/TEN, with the aim of improving patient outcomes and understanding the disease and its mechanisms.

9 December 2008 in Current Allergy and Asthma Reports
Verified
Journal Article
Closed access
PDF file
YMYoshiko Mizukawa
Yoshiko Mizukawa
TSTetsuo Shiohara
Tetsuo Shiohara

15 August 2018 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
YUYukiko Ushigome
Yukiko Ushigome
YMYoshiko Mizukawa
Yoshiko Mizukawa
MKMomoko Kimishima
Momoko Kimishima
YYYoshimi Yamazaki
Yoshimi Yamazaki
RTRyo Takahashi
Ryo Takahashi
TSTetsuo Shiohara
Tetsuo Shiohara